# Procyrion, Inc.

> Procyrion, Inc. is a Houston-based medical device company developing Aortix, a catheter-delivered percutaneous mechanical circulatory support (pMCS) pump. About the width of a pencil, Aortix is anchored in the descending aorta where it unloads the failing heart while boosting blood flow to the kidneys, targeting acute decompensated heart failure and cardiorenal syndrome. The device holds FDA Breakthrough Device Designation and is in the DRAIN-HF pivotal IDE trial after closing a $57.7M Series E in February 2024.

- **Founded:** 2005
- **Headquarters:** Houston, Texas, United States
- **Founders:** Reynolds M. Delgado III, MD, FACC (Founder & Chief Medical Officer)
- **Team size:** ~28-34 employees
- **Products:** Aortix
- **Notable:** FDA Breakthrough Device Designation for the Aortix System (July 2019), Named to Fierce Medtech's 'Fierce 15' of 2023, Successful first-in-human cases in cardiorenal syndrome patients (2021)

## Products & services

- **Aortix** — A catheter-delivered percutaneous mechanical circulatory support pump, roughly 6mm in diameter, deployed through the femoral artery and anchored in the descending thoracic aorta. Using a jet-entrainment mechanism, it pulls surrounding blood along to reduce afterload on the failing heart while increasing pressure and flow to the kidneys to improve renal perfusion. Deployment takes under ~10 minutes. Holds FDA Breakthrough Device Designation; investigational, not yet approved for sale.

## Achievements

- FDA Breakthrough Device Designation for the Aortix System (July 2019)
- Named to Fierce Medtech's 'Fierce 15' of 2023
- Successful first-in-human cases in cardiorenal syndrome patients (2021)
- Closed $57.7M Series E financing (February 2024)
- Launched DRAIN-HF pivotal IDE trial with first patient enrollments (November 2023)
- First-in-human study showed up to a ten-fold increase in urine output

## Latest updates

- **2025-12** — Andrew Davis appointed Chief Commercial Officer, a signal toward commercialization.
- **2024-09** — Lucas Buchanan appointed to the Board of Directors.
- **2024-02** — Closed $57.7M Series E financing led by Fannin Partners to fund the DRAIN-HF pivotal trial and commercialization prep.
- **2023-11** — Announced first patient enrollments in the DRAIN-HF pivotal IDE trial (NCT05677100).
- **2023-01** — Recognized in Fierce Medtech's Fierce 15 of 2023.

## Links

- Website: https://procyrion.com
- LinkedIn: https://www.linkedin.com/company/procyrion
- Twitter/X: https://twitter.com/Procyrion

---

Profile page: https://yespress.io/procyrion-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13